Abstract:Acute hepatitis C virus (HCV) infection is a global health concern with substantial geographical variation in the incidence rate. People who have received unsafe medical procedures, used injection drugs, and lived with human immunodeficiency virus are reported to be most susceptible to acute HCV infection. The diagnosis of acute HCV infection is particularly challenging in immunocompromised, reinfected, and superinfected patients due to difficulty in detecting anti-HCV antibody seroconversion and HCV ribonucleic acid from a previously negative antibody response. With an excellent treatment effect on chronic HCV infection, recently, clinical trials investigating the benefit of direct-acting antivirals (DAAs) treatment for acute HCV infection have been conducted. Based on the results of cost-effectiveness analysis, DAAs should be initiated early in acute HCV infection prior to spontaneous viral clearance. Compared to the standard 8-12 week-course of DAAs for chronic HCV infection, DAAs treatment duration may be shortened to 6-8 weeks in acute HCV infection without compromising the efficacy. Standard DAA regimens provide comparable efficacy in treating HCV-reinfected patients and DAA-naïve ones. For cases contracting acute HCV infection from HCV-viremic liver transplant, a 12-week course of pangenotypic DAAs is suggested. While for cases contracting acute HCV infection from HCV-viremic non-liver solid organ transplants, a short course of prophylactic or pre-emptive DAAs is suggested. Currently, prophylactic HCV vaccines are unavailable. In addition to treatment scale-up for acute HCV infection, practice of universal precaution, harm reduction, safe sex, and vigilant surveillance after viral clearance remain critical in reducing HCV transmission.

Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review

Clinical efficacy and safety of ravidavir-based antiretroviral regimen in treatment of patients with chronic hepatitis C

Recent progress in direct-acting antiviral agents for chronic hepatitis C

Characteristics of chronic hepatitis C in the elderly and the progress of antiviral therapy

New advances in drug therapy of chronic hepatitis B infection

Recent Advance in Antiviral Drugs for Hepatitis C.

Recent Progress and Future Prospects of Direct-Acting Antiviral Agents for Chronic Hepatitis C

Updated treatment protocol for direct-acting antiviral agents for hepatitis C

Clinical practice of direct-acting antiviral agents for chronic HCV infection

Personalized care approaches to hepatitis C therapy: recent advances and future directions

New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges

[Selection of Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection].

[Recent Advances in the Treatment of Hepatitis C in 2016].

The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection

The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment

Key points for the management of hepatitis C in the era of pan-genotypic direct-acting antiviral therapy

Long-term Outcomes in Patients with Chronic Hepatitis C in the Current Era of Direct-Acting Antiviral Agents

Acute hepatitis C virus infection: clinical update and remaining challenges

Advances and new strategies for the treatment of chronic hepatitis B

Vitamin D deficiency in hepatitis C virus infection: what is old? what is new?

Barriers to Treatment of Hepatitis C Virus in the Direct-Acting Antiviral Era